CA2223014A1 - Controlled release formulation having a preformed passageway - Google Patents

Controlled release formulation having a preformed passageway

Info

Publication number
CA2223014A1
CA2223014A1 CA002223014A CA2223014A CA2223014A1 CA 2223014 A1 CA2223014 A1 CA 2223014A1 CA 002223014 A CA002223014 A CA 002223014A CA 2223014 A CA2223014 A CA 2223014A CA 2223014 A1 CA2223014 A1 CA 2223014A1
Authority
CA
Canada
Prior art keywords
controlled release
passageway
release formulation
tablet
preformed passageway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002223014A
Other languages
French (fr)
Other versions
CA2223014C (en
Inventor
Chih-Ming Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrx Pharmaceuticals LLC
Original Assignee
Andrx Pharmaceuticals, Inc.
Chih-Ming Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/476,455 external-priority patent/US5654005A/en
Application filed by Andrx Pharmaceuticals, Inc., Chih-Ming Chen filed Critical Andrx Pharmaceuticals, Inc.
Publication of CA2223014A1 publication Critical patent/CA2223014A1/en
Application granted granted Critical
Publication of CA2223014C publication Critical patent/CA2223014C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

A controlled release pharmaceutical tablet having at least one passageway, said tablet having: (a) a compressed core which comprises:
(i) a medicament; (ii) an amount of a water soluble osmotic agent which is effective to cause the medicament to be delivered from said passageway in the presence of aqueous media; (iii) a water-swellable pharmaceutically acceptable polymer, and (b) a membrane coating around said core tablet which comprises a water insoluble pharmaceutically acceptable polymer.
CA002223014A 1995-06-07 1996-06-05 Controlled release formulation having a preformed passageway Expired - Fee Related CA2223014C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/476,455 US5654005A (en) 1995-06-07 1995-06-07 Controlled release formulation having a preformed passageway
US08/476,455 1995-06-07
PCT/US1996/008869 WO1996040080A1 (en) 1995-06-07 1996-06-05 Controlled release formulation having a preformed passageway

Publications (2)

Publication Number Publication Date
CA2223014A1 true CA2223014A1 (en) 1996-12-19
CA2223014C CA2223014C (en) 2006-02-14

Family

ID=35892321

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002223014A Expired - Fee Related CA2223014C (en) 1995-06-07 1996-06-05 Controlled release formulation having a preformed passageway

Country Status (1)

Country Link
CA (1) CA2223014C (en)

Also Published As

Publication number Publication date
CA2223014C (en) 2006-02-14

Similar Documents

Publication Publication Date Title
AU6042796A (en) Controlled release formulation having a preformed passageway
CA2217226A1 (en) Controlled release formulation for water soluble drugs in which a passageway is formed in situ
CA2269707A1 (en) Soluble form osmotic dose delivery system
CA2039456A1 (en) Osmotic dosage system for liquid drug delivery
CA2315329A1 (en) Improved hmg coa reductase inhibitor extended release formulation
CA2306333A1 (en) Oral morphine multiparticulate formulation
CA2198630A1 (en) Acetaminophen sustained-release formulation
CA2271306A1 (en) Pharmaceutical suspension systems
CA2136411A1 (en) Immediate Release Tablet Cores of Insoluble Drugs Having Sustained Release Coating
CA2351814A1 (en) Taste masked pharmaceutical particles
CA2242986A1 (en) Sustained release drug formulations
CA2343376A1 (en) Sustained release ranolazine formulations
EP0213083A3 (en) Controlled release tablet
CA2337046A1 (en) Sustained release pharmaceutical preparation
WO2001078725A3 (en) Modified release formulations containing a hypnotic agent
CA2376226A1 (en) New formulation
GR3003734T3 (en)
EP0839527A3 (en) Film coated tablet compositions having enhanced disintegration characteristics
CA2119932A1 (en) Pressurized hydrofluoroalkane pharmaceutical aerosol compositions
CA2312710A1 (en) Sustained release formulation containing three different types of polymers and tablet formed therefrom
CA2333869A1 (en) Mousse composition
CA2186039A1 (en) New oral pharmaceutical dosage form
ZA997727B (en) Pharmaceutical composition for application to mucosa.
CA2352211A1 (en) Sustained release matrix systems for highly soluble drugs
WO2002024174A3 (en) Sustained release composition containing clarithromycin

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140605